Gene · 7874
NIH grants2,023
NIH grants whose papers are about the gene, through NIH's grant-paper links.
61 to 80 of 2,023
Download this page as JSON| Grant | Title | USP7 papers | Newest fiscal year |
|---|---|---|---|
| P30CA125123 | Baylor College of Medicine Cancer Center - Cancer Center Support Grant | 2 | 2025 |
| P30CA138292 | Winship Cancer Institute Cancer Center Support Grant | 2 | 2025 |
| P30ES006694 | Southwest Environmental Health Sciences Center | 2 | 2025 |
| P30GM124165 | NE-CAT: A Resource for Advanced Macromolecular Crystallography | 2 | 2025 |
| P30GM133894 | A Synchrotron Radiation Structural Biology Resource | 2 | 2025 |
| P50CA092629 | SPORE in Prostate Cancer | 2 | 2025 |
| P50CA097190 | Head and Neck Cancer SPORE | 2 | 2025 |
| P50CA101942 | DF/HCC Kidney Cancer SPORE (supplement) | 2 | 2025 |
| P50CA168504 | Dana Farber/Harvard Cancer Center Specialized Program of Research Excellence in Breast Cancer | 2 | 2025 |
| R01AI127465 | Effector-mediated ubiquitin manipulation in Legionella pneumophila pathogenesis | 2 | 2025 |
| R01CA074305 | Chemical Approaches to Cell Signaling Enzymes | 2 | 2025 |
| R01CA102184 | Functional Analysis of p53 Polymorphic Variants | 2 | 2025 |
| R01CA196643 | Mechanisms of metabolic reprogramming by PIK3CA oncogenic mutations | 2 | 2025 |
| R01CA198279 | Shaping DNA Damage Response Networks Via Histone H2A Variants | 2 | 2025 |
| R01CA214608 | The molecular basis of IMiD induced neo-substrate recruitment to the CRL4CRBN ubiquitin E3 ligase | 2 | 2025 |
| R01CA218278 | Degrading therapeutically important kinases using small molecules | 2 | 2025 |
| R01CA252239 | Dynamic 3D chromatin remodeling in acute leukemia - Resubmission - 1 | 2 | 2025 |
| R01CA254970 | Novel small molecule USP7 Inhibitors for p53 activation and cancer therapy | 2 | 2025 |
| R01CA258100 | Targeting m6A RNA epigenetics in treatment-emergent neuroendocrine prostate cancer | 2 | 2025 |
| R01CA260028 | Remodeling of 3D chromatin in B cell acute leukemia and its impact on clinical outcome | 2 | 2025 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/7874/grants?page=4